ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,626.44
      -0.12%
      US Tech 100
      18,913.20
      -0.09%
      Dow Jones
      41,548.56
      -0.18%
      Brent Oil
      73.39
      1.07%
      Bitcoin
      59,953.99
      3.04%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Caribou Biosciences Inc (CRBU) Quote

      Caribou Biosciences Inc

      Caribou Biosciences Inc (CRBU)

      Amd Commo Exagr
      2.105
      0.075
      ( 3.69% )
      Updated: 15:30:18
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      2.105
      Bid
      2.10
      Ask
      2.11
      Volume
      619,488
      2.03 Day's Range 2.19
      1.50 52 Week Range 8.33
      Market Cap
      190.214M
      Previous Close
      2.03
      Open
      2.04
      Last Trade
      23
      @
      2.1047
      Last Trade Time
      15:31:26
      Financial Volume
      $ 1,303,842
      VWAP
      2.1047
      Average Volume (3m)
      1,474,058
      Shares Outstanding
      90,362,771
      Dividend Yield
      -
      PE Ratio
      -1.86
      Earnings Per Share (EPS)
      -1.13
      Revenue
      34.48M
      Net Profit
      -102.07M

      About Caribou Biosciences Inc

      Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.cariboubio.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $2.03. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 1.50 to $ 8.33.

      Caribou Biosciences currently has 90,362,771 shares outstanding. The market capitalization of Caribou Biosciences is $183.44 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.86.

      Ask ADVFN Intelligence (AI)

      CRBU Latest News

      More News

      FeaturedMawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt

      7 hours ago

      Form 8-K - Current report

      September 03 2024
      Edgar (US Regulatory)

      Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

      -- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...

      September 03 2024
      GlobeNewswire Inc.

      Caribou Biosciences to Participate in Upcoming Investor Conferences

      BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company...

      August 26 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 20 2024
      Edgar (US Regulatory)

      Form 3 - Initial statement of beneficial ownership of securities

      August 20 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 12 2024
      Edgar (US Regulatory)

      Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

      -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE...

      August 12 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 06 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 06 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.29516.29834254141.812.191.758158322.02676538CS
      4-0.095-4.318181818182.22.311.639602271.98497412CS
      120.24513.17204301081.862.7451.514740582.10427725CS
      26-3.455-62.14028776985.565.771.519079122.79368287CS
      52-3.685-63.64421416235.798.331.517485034.02123493CS
      156-25.395-92.345454545527.527.951.512374206.19432842CS
      260-15.545-88.073654390917.6532.6451.512259816.88590818CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      GLMDGalmed Pharmaceuticals Ltd
      $ 18.10
      (367.70%)
      		91.27M
      SMSISmith Micro Software Inc
      $ 1.025
      (95.98%)
      		162.17M
      BFIBurgerFi International Inc
      $ 0.2263
      (87.02%)
      		220.5M
      WHLRLWheeler Real Estate Investment Trust Inc
      $ 148.50
      (70.85%)
      		2.29k
      IOBTIO Biotech Inc
      $ 1.27
      (63.83%)
      		3.19M
      OMEXOdyssey Marine Exploration Inc
      $ 0.77
      (-83.55%)
      		987.21k
      SWVLSwvl Holdings Corporation
      $ 3.13
      (-42.14%)
      		386.13k
      PGHLPrimega Group Holdings Ltd
      $ 10.61
      (-41.99%)
      		951.51k
      NCNANuCana PLC
      $ 3.875
      (-39.17%)
      		2.88M
      NKGNNKGen Biotech Inc
      $ 0.5083
      (-31.77%)
      		1.11M
      BFIBurgerFi International Inc
      $ 0.2263
      (87.02%)
      		246.44M
      NVDANVIDIA Corporation
      $ 115.2699
      (-1.29%)
      		191.48M
      INTCIntel Corporation
      $ 21.40
      (2.34%)
      		173.48M
      SMSISmith Micro Software Inc
      $ 1.031
      (97.13%)
      		165.28M
      SQQQProShares UltraPro Short QQQ
      $ 8.35
      (0.60%)
      		121.66M

      CRBU Discussion

      View Posts
      Monksdream Monksdream 2 weeks ago
      CRBU under $3
      👍️0
      Monksdream Monksdream 2 months ago
      CRBU under $3
      👍️0
      jondoeuk jondoeuk 2 months ago
      Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

      This should extend their cash runway by at least six months, into the second half of 2026.
      👍️0
      Monksdream Monksdream 2 months ago
      CRBU under $3
      👍️0
      Monksdream Monksdream 3 months ago
      CRBU new 52 week low
      👍️0
      Monksdream Monksdream 3 months ago
      CRBU new 52 week low
      👍️0
      NY1972 NY1972 3 months ago
      Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
      👍️0
      Diego Rivas Diego Rivas 3 months ago
      Any good news in here comming?
      👍️0
      jondoeuk jondoeuk 3 months ago
      Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
      👍️0
      jondoeuk jondoeuk 3 months ago
      The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

      * CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
      👍️0
      Monksdream Monksdream 3 months ago
      CRBU new 52 week low
      👍️0
      stocksrising stocksrising 3 months ago
      Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
      👍️0
      jondoeuk jondoeuk 4 months ago
      It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
      👍️ 1
      Monksdream Monksdream 4 months ago
      CRBU new 52 week low
      👍️0
      Monksdream Monksdream 4 months ago
      CRBU new 52 week low
      👍️0
      Monksdream Monksdream 5 months ago
      CRBU under $5
      👍️0
      stocksrising stocksrising 6 months ago
      It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
      👍️0
      Monksdream Monksdream 11 months ago
      CRBU new 52 week low
      👍️0
      jondoeuk jondoeuk 1 year ago
      Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

      Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
      👍️0
      trueblue trueblue 1 year ago
      .
      👍️0
      trueblue trueblue 1 year ago
      $23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
      👍️0
      NY1972 NY1972 1 year ago
      Didn't they buy TRIL? Just gambling with billions from US government.
      👍️0
      jondoeuk jondoeuk 1 year ago
      PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
      👍️0
      trueblue trueblue 1 year ago
      Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
      👍️0
      Monksdream Monksdream 1 year ago
      CRBU now No 9 on the Barchart Top 10
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      trueblue trueblue 1 year ago
      Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
      👍️0
      Stockexpertpro Stockexpertpro 1 year ago
      CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      CRBU= JUST WOW

      https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
      👍️0
      Monksdream Monksdream 1 year ago
      CRBU No 1 on the early Barchart Top 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0

      Your Recent History

      NASDAQ
      CRBU
      Caribou Biosciences
      Delayed Upgrade Clock